Combination of IRAK4 Inhibitor CA-4948 with BCL2 Inhibitor Venetoclax Induces Tumor Regression in an ABC-DLBCL Xenograft Model

被引：0
|
作者：
Booher, Robert
Dellarocca, Steven
Atoyan, Ruzanna
Borek, Mylissa
Samson, Maria Elena S.
Tuck, David
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1534
引用
收藏
页数：2
相关论文
共 16 条
  • [1] The IRAK4 inhibitor CA-4948 demonstrates antitumor activity in a preclinical model of CNS lymphoma
    von Roemeling, Christina A.
    Doonan, Bently P.
    Hoang-Minh, Lan
    Tun, Han W.
    Martinez, Elizabeth
    Soikes, Raul
    von Roemeling, Reinhard
    Mitchell, Duane A.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [2] Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies
    Gummadi, Venkateshwar Rao
    Boruah, Anima
    Ainan, Bharathi Raja
    Vare, Brahma Reddy
    Manda, Srinivas
    Gondle, Hari Prakash
    Kumar, Shiva Nagendra
    Mukherjee, Subhendu
    Gore, Suraj T.
    Krishnamurthy, Narasimha Rao
    Marappan, Sivapriya
    Nayak, Shilpa S.
    Nellore, Kavitha
    Balasubramanian, Wesley Roy
    Bhumireddy, Archana
    Giri, Sanjeev
    Gopinath, Sreevalsam
    Samiulla, Dodheri S.
    Daginakatte, Girish
    Basavaraju, Aravind
    Chelur, Shekar
    Eswarappa, Rajesh
    Belliappa, Charamanna
    Subramanya, Hosahalli S.
    Booher, Robert N.
    Ramachandra, Murali
    Samajdar, Susanta
    ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (12): : 2374 - 2381
  • [3] Efficacy of the IRAK4 inhibitor CA-4948 in patient-derived xenograft models of diffuse large B cell lymphoma
    Booher, Robert N.
    Samson, Maria Elena
    Xu, Guang-Xin
    Cheng, Hongsheng
    Tuck, David P.
    CANCER RESEARCH, 2017, 77
  • [4] Phase I trial of CA-4948, an IRAK4 inhibitor, in combination with FOLFOX/PD-1 inhibitor plus /- trastuzumab for untreated unresectable gastric and esophageal cancer
    Park, Haeseong
    Iglesia, Michael
    Pedersen, Katrina Sophia
    Grierson, Patrick
    Hu, Zishuo Ian
    Suresh, Rama
    Tan, Benjamin R.
    Trikalinos, Nikolaos
    Aranha, Olivia
    Navo, Katherine
    DeNardo, David G.
    Ciorba, Matthew A.
    Kraft, Katlyn
    Gao, Feng
    Martinez, Elizabeth
    Von Roemeling, Reinhard
    Geissler, Felix
    Lim, Kian-Huat
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Phase 1/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia or lyelodysplastic syndrome.
    Garcia-Manero, Guillermo
    Winer, Eric S.
    DeAngelo, Daniel J.
    Tarantolo, Stefano R.
    Sallman, David Andrew
    Dugan, James
    Groepper, Stefanie
    Giagounidis, Aristoteles
    Gotze, Katharina S.
    Metzeler, Klaus
    Li, Chia-Cheng
    Zhou, Li
    Martinez, Elizabeth
    Lane, Maureen E.
    Von Roemeling, Reinhard W.
    Bohme, Matthias
    Kubasch, Anne Sophie
    Verma, Amit K.
    Platzbecker, Uwe
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma
    Booher, Robert N.
    Nowakowski, Grzegorz S.
    Patel, Krish
    Lunning, Matthew A.
    Samson, Maria Elena S.
    Atoyan, Ruzanna
    Ma, Anna W.
    Xu, Guang-Xin
    Dellarocca, Steven
    Modafferi, Holly
    Borek, Mylissa
    Zhang, Zhidong
    Parker, Jefferson
    Whitney, Duncan
    Wang, Hongwei
    Tuck, David P.
    Younes, Anas
    BLOOD, 2018, 132
  • [7] Preclinical evaluation of a novel interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor in combination with PI3K inhibitor copanlisib or BTK inhibitors in ABC-DLBCL
    Lange, Martin
    Wengner, Antje Margret
    Bothe, Ulrich
    Boemer, Ulf
    Nubbemeyer, Reinhard
    Siebeneicher, Holger
    Steuber, Holger
    Guenther, Judith
    Potze, Lisette
    Schmidt, Nicole
    Politz, Oliver
    Doecke, Wolf-Dietrich
    Lagkadinou, Eleni
    Zollner, Thomas M.
    von Nussbaum, Franz
    Mumberg, Dominik
    Steinmeyer, Andreas
    Brands, Michael
    Ziegelbauer, Karl
    CANCER RESEARCH, 2018, 78 (13)
  • [8] Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study
    Nowakowski, Grzegorz S.
    Leslie, Lori A.
    Younes, Anas
    Rosenthal, Allison C.
    Lunning, Matthew A.
    Patel, Krish
    Landsburg, Daniel J.
    Martinez, Elizabeth
    von Roemeling, Reinhard
    Lieberman, Christopher
    Tun, Han W.
    BLOOD, 2020, 136
  • [9] Identification of NF-kappaB phospho-p50 as a predictive biomarker for IRAK4 inhibitor CA-4948 in patients with non-Hodgkin's lymphoma.
    Ugolkov, Andrey
    Samson, Maria
    Hok, Rosanna
    Von Roemeling, Reinhard
    Martell, Robert
    CANCER RESEARCH, 2021, 81 (13)
  • [10] KYM-001, a first-in-class oral IRAK4 protein degrader, induces tumor regression in xenograft models of MYD88-mutant ABC DLBCL alone and in combination with BTK inhibition
    Kelleher, Joseph F.
    Campbell, Veronica
    Chen, Jesse
    Gollob, Jared
    Ji, Nan
    Kamadurai, Hari
    Klaus, Christine
    Li, Henry
    Loh, Christine
    McDonald, Alice
    Rong, Haojing
    Rusin, Scott
    Sharma, Kirti
    Vigil, Dominico
    Walker, Duncan
    Weiss, Matt
    Yuan, Karen
    Zhang, Yi
    Audoly, Laurent
    Mainolfi, Nello
    CANCER RESEARCH, 2019, 79 (13)
12